文献速递中药与中成药合理使用中医内科

喜炎平注射液与洛匹那韦/利托那韦的草药-药物相互作用研究

Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy.
PubMed 文献 · Front Pharmacol · 2021-11-11

本研究旨在验证喜炎平注射液(XYPI)对洛匹那韦(LPV)/利托那韦(RTV)口服药代动力学的影响,采用大鼠体内模型和人肝微粒体体外孵育模型。结果显示,连续7天XYPI预处理后,LPV的t1/2从4.66延长至7.18 h(p<0.05),RTV的AUC0-∞从0.69升至2.72 h μg/mL(p<0.05),CL从2.71降至0.94 L/h(p<0.05),t1/2从3.70延长至5.51 h(p<0.05)。体外研究表明XYPI以非竞争性方式抑制人CYP3A4,Ki值为0.54 mg/ml。

要点

  • 连续7天XYPI预处理可显著改变RTV的药代动力学参数。
  • XYPI通过非竞争性抑制CYP3A4活性影响LPV/RTV代谢。
  • 临床联用需警惕潜在药物相互作用风险。

核心结论

  • 喜炎平注射液通过抑制CYP3A4活性影响洛匹那韦/利托那韦的药代动力学。

研究设计与样本

  • 研究采用大鼠体内药代动力学模型和人肝微粒体体外孵育模型。
  • 大鼠经静脉给予XYPI(52.5 mg/kg)预处理1天或连续7天,后口服LPV/RTV(42:10.5 mg/kg)。

主要发现

  • 连续7天XYPI预处理后,LPV的t1/2从4.66显著延长至7.18 h(p<0.05),其他参数变化轻微。
  • 连续7天预处理后,RTV的AUC0-∞从0.69显著升高至2.72 h μg/mL(p<0.05)。
  • 连续7天预处理后,RTV的CL从2.71趋向降低至0.94 L/h(p<0.05),t1/2从3.70延长至5.51 h(p<0.05)。
  • XYPI给药后大鼠Cyp3a1蛋白表达无显著变化。
  • 体外研究显示XYPI以时间依赖方式非竞争性抑制人CYP3A4,Ki值为0.54 mg/ml。

临床怎么用

  • COVID-19治疗中联用XYPI与LPV/RTV时,患者和临床医生应采取预防措施避免潜在药物相互作用风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The global epidemic outbreak of the coronavirus disease 2019 (COVID-19), which exhibits high infectivity, resulted in thousands of deaths due to the lack of specific drugs. Certain traditional Chinese medicines (TCMs), such as Xiyanping injection (XYPI), have exhibited remarkable benefits against COVID-19. Although TCM combined with Western medicine is considered an effective approach for the treatment of COVID-19, the combination may result in potential herb-drug interactions in the clinical setting. The present study aims to verify the effect of XYPI on the oral pharmacokinetics of lopinavir (LPV)/ritonavir (RTV) using an in vivo rat model and in vitro incubation model of human liver microsomes. After being pretreated with an intravenous dose of XYPI (52.5 mg/kg) for one day and for seven consecutive days, the rats received an oral dose of LPV/RTV (42:10.5 mg/kg). Except for the t1/2 of LPV is significantly prolonged from 4.66 to 7.18 h (p < 0.05) after seven consecutive days pretreatment, the pretreatment resulted in only a slight change in the other pharmacokinetic parameters of LPV. However, the pharmacokinetic parameters of RTV were significantly changed after pretreatment with XYPI, particularly in treatment for seven consecutive days, the AUC0-∞ of RTV was significantly shifted from 0.69 to 2.72 h μg/mL (p < 0.05) and the CL exhibited a tendency to decrease from 2.71 L/h to 0.94 L/h (p < 0.05), and the t1/2 of RTV prolonged from 3.70 to 5.51 h (p < 0.05), in comparison with the corresponding parameters in untreated rats. After administration of XYPI, the expression of Cyp3a1 protein was no significant changed in rats. The in vitro incubation study showed XYPI noncompetitively inhibited human CYP3A4 with an apparent Ki value of 0.54 mg/ml in a time-dependent manner. Our study demonstrated that XYPI affects the pharmacokinetics of LPV/RTV by inhibiting CYP3A4 activity. On the basis of this data, patients and clinicians can take precautions to avoid potential drug-interaction risks in COVID-19 treatment.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ye L, Cheng L, Deng Y, et al. Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy. Front Pharmacol. 2021. PMID: 34899329. doi:10.3389/fphar.2021.773126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。